Apotex Receives FDA Approval for First Generic Infuvite Adult Injection with 180-Day Exclusivity

Key Takeaways

• Apotex becomes first company to receive FDA approval for generic Infuvite Adult Injection in both single dose and pharmacy bulk package formats
• The pharmacy bulk package version receives 180-day Competitive Generic Therapy (CGT) exclusivity, providing temporary market protection
• Partnership with Orbicular Pharmaceutical Technologies and Gland Pharma Limited strengthens Apotex’s generic injectable portfolio

---

Apotex Secures Landmark FDA Approval for Generic Infuvite

Apotex Corp. announced on April 14, 2026, that the U.S. Food and Drug Administration has approved two Abbreviated New Drug Applications (ANDAs) for the first generic version of Infuvite® Adult Injection, marking a significant milestone in the injectable vitamins market.

Partnership Strategy Drives Success

The approval comes through a strategic collaboration between Apotex Corp., Orbicular Pharmaceutical Technologies Pvt. Ltd., and Gland Pharma Limited. Apotex serves as the ANDA applicant and will lead commercialization efforts for both the single dose vial and pharmacy bulk package formulations.

Market Exclusivity Provides Competitive Edge

The pharmacy bulk package version has received 180-day Competitive Generic Therapy (CGT) exclusivity, a designation that provides temporary market protection for generic manufacturers who successfully challenge brand-name drug patents or overcome regulatory barriers. This exclusivity period allows Apotex to establish market presence before additional generic competitors enter.

Clinical and Commercial Impact

Infuvite Adult Injection is a multivitamin preparation used in hospitals and clinical settings for patients requiring intravenous nutritional support. The availability of a generic alternative is expected to reduce healthcare costs while maintaining the same therapeutic benefits as the brand-name product.

The dual-format approval strategy addresses different healthcare facility needs: single dose vials for smaller institutions and pharmacy bulk packages for larger hospital systems that prepare multiple doses.

Industry Implications

This approval reinforces Apotex’s position in the competitive generic injectables market, a segment that requires significant manufacturing expertise and regulatory compliance. The successful partnership model demonstrated here may influence future collaborative approaches in generic drug development.

The CGT exclusivity designation highlights the FDA’s continued efforts to incentivize generic competition in markets with limited alternatives, ultimately benefiting patients through increased access and affordability.

---

Frequently Asked Questions

What does this approval mean for patients?

Patients will have access to a more affordable generic alternative to brand-name Infuvite Adult Injection, potentially reducing healthcare costs while receiving the same therapeutic benefits for intravenous nutritional support.

When will generic Infuvite Adult Injection be available?

While the FDA approval has been granted, Apotex has not announced a specific launch date. The company will likely begin commercialization during the 180-day exclusivity period for the pharmacy bulk package.

How does the 180-day CGT exclusivity work?

The Competitive Generic Therapy exclusivity gives Apotex 180 days of market protection for the pharmacy bulk package, meaning no other generic versions can be approved during this period, allowing them to establish market presence before additional competition.